Use of Polymyxins in Chinese Hospitals

Rong Zhang,Yingbo Shen,Timothy R. Walsh,Yang Wang,Fupin Hu
DOI: https://doi.org/10.1016/s1473-3099(20)30696-4
2020-01-01
Abstract:We acknowledge the Comment from Federico Perez and Robert A Bonomo1Perez F Bonomo RA Colistin resistance in China: from outer membrane to One Health.Lancet Infect Dis. 2020; (published online June 4.)https://doi.org/10.1016/S1473-3099(20)30242-5Summary Full Text Full Text PDF Scopus (2) Google Scholar regarding our Article2Wang Y Xu C Zhang R et al.Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study.Lancet Infect Dis. 2020; 20: 1161-1171Summary Full Text Full Text PDF PubMed Scopus (125) Google Scholar on the decline of colistin resistance and mcr-1 abundance in Escherichia coli from animal and human origins following the ban of colistin as an animal growth promoter in China. We appreciate their suggestion that the insufficient data on clinical polymyxin use is a limitation of our study. From the introduction of polymyxin in the 1980s, its use in China was restricted to food-producing animals. However, in January, 2017, the China Food and Drug Administration (CFDA) approved polymyxin B as a therapy in humans,3National Medical Products AdministrationData query.http://app1.nmpa.gov.cn/data_nmpa/face3/dir.html?Date: 2018Date accessed: August 6, 2020Google Scholar and injectable polymyxin B (lyophilised powder, 500 000 units per dose) became available for clinical use in October, 2017. In May, 2018, the CFDA also approved colistin (polymyxin E) for exclusive use in humans,3National Medical Products AdministrationData query.http://app1.nmpa.gov.cn/data_nmpa/face3/dir.html?Date: 2018Date accessed: August 6, 2020Google Scholar and injectable colistin (lyophilised powder, 500 000 units per dose) became available for clinical use in December, 2018. We collected hospital consumption data for polymyxins, including polymyxin B (2018–19) and colistin (2019), from 26 Chinese provinces using the CHINET surveillance system, and compared the data with samples that were positive for colistin-resistant E coli from the corresponding provinces in 2018–19.2Wang Y Xu C Zhang R et al.Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study.Lancet Infect Dis. 2020; 20: 1161-1171Summary Full Text Full Text PDF PubMed Scopus (125) Google Scholar In total, 354 442 polymyxin doses were administered between 2018 and 2019. More than 10 000 doses were given to patients who were hospitalised in ten provinces. Nine of the ten provinces (except Beijing) were among the top ten wealthiest areas in China (by gross domestic income in 2019, appendix p 1). Hospitals in Zhejiang, Jiangsu, Beijing, Shanghai, and Guangdong consumed over half (196 018 [55·3%] of 354 442 doses) of all polymyxin used for the treatment of serious multidrug-resistant infections, mainly caused by carbapenem-resistant Gram-negative bacilli. Notably, hospitals from five of these provinces are major referral centres and have some of the best resources in China. Based on consumption data, we conclude that Chinese clinicians should consider polymyxin as a last resort antibiotic, and that clinical polymyxin use should be heavily restricted. To understand the relationship between polymyxin use and infections caused by colistin-resistant E coli in Chinese hospitals, we did a correlation analysis. Spearman’s correlation coefficient showed no significant correlation between polymyxin use and colistin-resistant E coli (Spearman’s ρ=0·18, p=0·389). We propose three possible reasons for the absence of correlation. First, a large number of inpatients receiving polymyxin were treated in intensive care units and had little or no similarities of ward to inpatients who were positive for colistin-resistant E coli from other hospital units, including the intensive care unit.3National Medical Products AdministrationData query.http://app1.nmpa.gov.cn/data_nmpa/face3/dir.html?Date: 2018Date accessed: August 6, 2020Google Scholar Second, some inpatients who were positive for colistin-resistant E coli were administered antibiotics that were not polymyxin, including tigecycline and carbapenem plus fosfomycin combination therapies. Third, unlike animals, in which large quantities of colistin were used and associated with colistin resistance, the short term and smaller amounts of polymyxin used in Chinese hospitals had little direct pressure on the emergence of colistin-resistant E coli. Nevertheless, our data will be useful baseline data for future studies. With the increase in carbapenem-resistant pathogens causing clinical infections,4Hu F Guo Y Yang Y et al.Resistance reported from China antimicrobial surveillance network (CHINET) in 2018.Eur J Clin Microbiol Infect Dis. 2019; 38: 2275-2281Crossref PubMed Scopus (133) Google Scholar, 5Hu F Zhu D Wang F Wang M Current status and trends of antibacterial resistance in China.Clin Infect Dis. 2018; 67: S128-S134Crossref PubMed Scopus (140) Google Scholar polymyxin use in Chinese hospitals is also expected to increase; therefore, continuous surveillance of both polymyxin use and colistin-resistant E coli infections is warranted. RZ and YW report grants from the National Natural Science Foundation of China (81861138052 and 81861138051), as part of the submitted work. TRW reports a UK–China joint project obtained in 2018 from the UK Medical Research Council (MR/S013768/1), under the name “Determining the clinical and environmental impact, burden and cost of Extensively Drug Resistant Enterobacteriaceae in China HUB” (DETER-XDRE-CHINA-HUB). YS and FH declare no competing interests. Download .pdf (.27 MB) Help with pdf files Supplementary appendix Colistin resistance in China: from outer membrane to One HealthThe use of antibiotics anywhere could select antibiotic-resistant bacteria everywhere. Reducing the use of antibiotics in farm animals is consequently fundamental to preserve the current and future benefits of antibiotics for people. WHO ranks polymyxins among those antibiotics of the highest priority for reduction in animal use, given that they are of crucial importance to human medicine.1 Therefore, the use of polymyxins (chiefly in the form of colistin sulfate premix) to treat and prevent infections and promote the growth of food-producing animals for decades is problematic, in view of their use in recent years to treat human infections caused by extensively drug-resistant Acinetobacter spp, Pseudomonas aeruginosa, and Enterobacterales. Full-Text PDF Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative studyThe colistin withdrawal policy and the decreasing use of colistin in agriculture have had a significant effect on reducing colistin resistance in both animals and humans in China. However, continuous colistin monitoring is essential, in particular to act as an early warning system for colistin stewardship in Chinese hospitals. Full-Text PDF
What problem does this paper attempt to address?